Gynecologic Oncology | Specialty

The gynecologic oncology condition center is a comprehensive resource for clinical news and expert insights on gynecologic oncology. Read more at OncLive.

Dr Duska on PFS2 Data With Pembrolizumab and Chemoradiotherapy in Cervical Cancer

July 17th 2025

Linda R. Duska, MD, MPH, discusses PFS2 data with pembrolizumab plus chemoradiotherapy in newly diagnosed, high-risk cervical cancer.

Biomarker Testing and Treatment Selection in Advanced Endometrial Cancer

July 17th 2025

Panelists discuss how endometrial cancer treatment has been revolutionized through molecular subtyping into 4 distinct groups (POLE hypermutated, microsatellite instability-high, p53 mutated, and no specific molecular pathology), enabling personalized treatment approaches based on tumor biology rather than just staging.

Advanced Cervical Cancer: Novel Immunotherapy Combinations and Future Treatment Paradigms

July 17th 2025

Panelists discuss how the field is expanding with newer antibody-drug conjugates targeting TROP2, combination immunotherapy approaches, and the critical importance of HPV vaccination as prevention, while addressing social barriers to complex treatment regimens.

Dr Mayadev on a ctDNA Analysis of the CALLA Trial in Cervical Cancer

July 15th 2025

Jyoti Mayadev, MD, discusses the value of ctDNA as a prognostic biomarker for relapse and survival in patients with locally advanced cervical cancer.

Dostarlimab Plus Chemo Prolongs Time to First, Second Subsequent Therapy Regardless of Age in Endometrial Cancer

July 11th 2025

After 3 years of follow-up, dostarlimab plus chemotherapy was effective and tolerable in patients aged 70 years or older with endometrial cancer.

ADC Treatment Strategies in Cervical Cancer: Clinical Implementation and Emerging Treatment Options

July 10th 2025

Panelists discuss how tisotumab vedotin represents a practice-changing but modest improvement in cervical cancer treatment, with only 1.5-month progression-free survival benefit and notable ocular toxicities, while emphasizing the need for better patient access to required ophthalmologic monitoring.

Advanced Cervical Cancer Treatment Landscape: Clinical Decision-Making and Biomarker Integration

July 10th 2025

Panelists discuss how cervical cancer treatment guidelines have rapidly evolved to incorporate pembrolizumab across multiple settings, from locally advanced disease with positive nodes to metastatic disease, while emphasizing the importance of comprehensive biomarker testing including PD-L1 and HER2 status for optimal treatment selection.

Dr Pothuri on Current Unmet Needs in Recurrent/Advanced Endometrial Cancer

July 1st 2025

Bhavana Pothuri, MD, discusses remaining unmet needs for patients with recurrent/advanced endometrial cancer.

Recent Advances and Future Direction in Ovarian Cancer Treatments

July 1st 2025

Panelists discuss how the recent approval of avutometinib plus defactinib for KRAS-mutated low-grade serous ovarian cancer addresses a significant unmet need in this lethal disease, with the dual FAK/MEK inhibition approach showing impressive response rates despite requiring careful toxicity management.

The Evolving Ovarian Cancer ADC Landscape

July 1st 2025

Panelists discuss how the emerging pipeline of folate receptor-targeted antibody-drug conjugates, including rinatabart sesutecan (Rina-S) and other novel compounds, offers diverse payload options and potentially broader patient eligibility with different toxicity profiles, though sequencing strategies remain to be determined.

Selinexor Maintenance Displays Durable Benefit in TP53 Wild-Type Advanced/Recurrent Endometrial Cancer

June 25th 2025

Selinexor improved PFS, TFST, TSST, and PFS2 in TP53 wild-type advanced/recurrent endometrial cancer.

Mirvetuximab Soravtansine in Advanced Ovarian Cancer: Survival Benefits, Quality of Life, and Ocular Toxicity Management

June 24th 2025

Panelists discuss how mirvetuximab soravtansinerepresents a significant advancement for platinum-resistant ovarian cancer with folate receptor alpha expression, providing unprecedented overall survival benefits despite manageable ocular toxicities that are reversible with proper monitoring and dose modifications.

Evolving Maintenance Approaches: Clinical Trial Updates in Ovarian Cancer

June 24th 2025

Panelists discuss how the frontline immunotherapy landscape is evolving with promising but not yet practice-changing data from the KEYNOTE and FIRST trials, suggesting potential benefits when combining pembrolizumab with PARP inhibitors in specific biomarker-defined subgroups of patients with ovarian cancer.

Relacorilant/Nab-Paclitaxel Is Associated With Survival Improvement in Platinum-Resistant Ovarian Cancer After Short Platinum-Free Interval

June 20th 2025

Relacorilant plus nab-paclitaxel improved survival in platinum-resistant ovarian cancer with a primary platinum-free interval of 1 to 6 months.

Pembrolizumab Plus Chemoradiation Hits ORR End Point in Unresectable Vulvar Cancer

June 20th 2025

Pembrolizumab plus chemoradiation with maintenance pembrolizumab was safe and effective in unresectable vulvar cancer.

PD-L1 CPS Does Not Enrich the Efficacy of Atezolizumab/Bevacizumab and Chemo in Advanced Cervical Cancer

June 19th 2025

Atezolizumab plus bevacizumab and chemotherapy is active in patients with persistent or recurrent metastatic cervical cancer irrespective of PD-L1 CPS.

Dr Markman the Significance of PROs in Patients With Locally Advanced Cervical Cancer

June 19th 2025

Maurie Markman, MD, discussed the significance of patient-reported outcomes from the phase 3 OUTBACK trial in locally advanced cervical cancer.

Dr Duska on the Adoption of Pembrolizumab Plus Concurrent CRT as a SOC in Advanced Cervical Cancer

June 17th 2025

Linda R. Duska, MD, MPH, discusses the need for continued research with concurrent chemoradiation in high-risk advanced cervical cancer.

Navigating Frontline Maintenance Options for Advanced Ovarian Cancer

June 17th 2025

Panelists discuss how NCCN guidelines structure treatment options for advanced ovarian cancer around bevacizumab decisions and HRD status, with most experts favoring PARP inhibitor maintenance therapy for 2 to 3 years while carefully monitoring for long-term toxicities like MDS and secondary leukemias.

Biomarker-Driven Treatment Selection in Advanced Ovarian Cancer

June 17th 2025

Panelists discuss how molecular testing approaches in advanced ovarian cancer should include comprehensive upfront biomarker assessment including HRD testing, folate receptor testing, PD-L1, and HER2 evaluation, combined with germline genetic counseling to guide treatment decisions and maintenance therapy strategies.